[98]
Novopharm's second line of argument is that the documents disclosed under the Disclosure Order in accordance with s. 6(7) of the
Regulations
should be held as confidential under a Protective Order because Novopharm was able to satisfy the grounds for such an order under Rule 151 and Prothonotary Milczynski was clearly wrong to hold otherwise.